DDX53 and cancer: Therefore, to address the clinical applicability of HDAC1 inhibitors for controlling NANOGhi-refractory cancer, we first measured the viability of CT26 P0, CT26 P3, or CT26 P3-siNANOG cells after in vitro treatment with FK228, MS-275, or MGCD0103.